ERBB2 and colorectal carcinoma: As of April 2022, there were 11 FDA-approved anticancer compounds of marine origin and 23 marine anticancer drugs in clinical trials, of which six are related to the treatment of CRC by targeting HER2, 11 by microtubules, 1 by BCMA, and 1 by EGFR.